As King’s College London (KCL) scientists are once more in the headlines – this time with new ‘plug and play’ drug delivery technology that could offer a
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh